Streetbeat News

Products Services

SOLUSD

Matthew Sigel, a digital asset strategist at VanEck, will share his crypto outlook at Benzinga's Future of Digital Assets conference. Sigel's research includes Bitcoin, smart contract platforms, and emerging market crypto. He recently co-wrote a report on Solana (CRYPTO: SOL), predicting $8 billion in revenues for Solana token holders by 2030. He also noted Solana's 340% surge in 2023, outperforming Bitcoin's 114% rise.

Portfolio Pulse from Stjepan Kalinic

November 09, 2023 | 5:44 pm

ATRA

Atara Biotherapeutics announced that its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis did not meet the primary endpoint of confirmed disability improvement. Following this announcement, multiple firms downgraded the stock.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:37 pm

LLY

Eli Lilly's shares are trading lower despite the FDA approval of Zepbound for chronic weight management. The stock had gained on Wednesday following the approval.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:29 pm

NVDA

NVIDIA is reportedly planning to introduce three new AI chips for the Chinese market, which has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:05 pm

MU

Micron Technology, Inc. is reportedly showcasing its latest technologies at the China International Import Expo, which has led to an increase in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:54 pm

SIRI

SiriusXM CEO Jennifer Witz appeared on CNBC to discuss the company's new app and streaming plan, now priced at $9.99. The discussion took place during Liberty Media Investor Day.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:42 pm

PHVS

Pharvaris (NASDAQ:PHVS) announced the presentation of two ePosters at the ACAAI 2023 Annual Scientific Meeting. The posters will present clinical data on Deucrictibant, a drug being developed to treat hereditary angioedema (HAE), and real-world HAE treatment satisfaction data. The phase 2 RAPIDe-1 trial showed that PHVS416 (immediate-release deucrictibant capsules) reduced time to symptom relief and use of rescue medication. The company aims to develop this formulation to provide rapid and reliable symptom relief in an easy-to-administer, small oral dosage form.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:08 pm

SPRY

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced that clinical data supporting neffy (epinephrine nasal spray) will be presented at the 2023 American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting. The data suggests that neffy could be a safe and effective option for treating severe allergic reactions across various patient subgroups. Notably, the pharmacokinetics of neffy are independent of BMI or body weight, unlike injection products.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:05 pm

LYFT

EVCS and Lyft Inc. (NASDAQ:LYFT) have announced a new partnership program that offers discounted charging on the EVCS network for Lyft's EV drivers. The program is available to all EV drivers on Lyft and covers all EVCS publicly accessible charging stations across California, Oregon, and Washington. The program aims to accelerate the transition to clean transportation in these states and aligns with California's Clean Miles Standard, which mandates 90% of rideshare vehicle miles traveled to be zero-emissions by 2030.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 4:04 pm

LLY

NVO

SNY

UNH

Optum Rx, a pharmacy services company, is taking additional steps to make insulin more affordable. Starting from Jan. 1, 2024, it will place eight preferred insulin products on tier one of standard commercial formularies, limiting out-of-pocket spend to $35 or less. This move is part of Optum Rx's ongoing efforts to improve access and make critical medications more affordable. The products of three manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, will be added to tier one. Optum Rx also supported UnitedHealthcare in eliminating copays for consumers in group fully insured plans for insulin and other critical drugs.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 3:55 pm